Abstracts tagged "animal models and signal transduction"

Abstract Number: 2355 • 2014 ACR/ARHP Annual Meeting
Apremilast, a Novel Phosphodiesterase 4 Inhibitor, and Methotrexate Independently Prevent Inflammation in Vivo and in Vitro
Miguel Perez-Aso¹, M. Carmen Montesinos², Aranzazu Mediero³, Peter H. Schafer⁴ and Bruce N. Cronstein⁵, ¹545 1st Ave., New York University, New York City, NY, ²Departament de Farmacologia, Facultat de Farmàcia,, Universitat de València, Valencia, Spain, ³Medicine, Division of Translational Medicine, NYU School of Medicine, New York, NY, ⁴Celgene Corporation, Celgene Corporation, Summit, NJ, ⁵NYU School of Medicine, Division of Rheumatology, New York, NY
Background/Purpose Phosphodiesterase 4 (PDE4) inhibitors have clear immunoregulatory effects in laboratory studies, and the clinical application of this class of drug in the field of…
Abstract Number: 2076 • 2012 ACR/ARHP Annual Meeting
Efficacy of the Potent PI3K-δ,γ Inhibitor IPI-145 in Rat Adjuvant Arthritis
David L. Boyle¹, Katharyn Topoleweski¹ and Gary S. Firestein², ¹Div of Rheum, UCSD School of Medicine, La Jolla, CA, ²Div of Rheumatology, UCSD School of Medicine, La Jolla, CA
Background/Purpose: Phosphoinositide 3-kinase (PI3K) is a family of intracellular signaling transducers and could be targeted to treat inflammatory diseases like rheumatoid arthritis (RA). However, blockade…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].